Current Trends of Combination Therapy in Chronic Hepatitis B Management in China
Journal Title: Archives of Hepatitis Research - Year 2015, Vol 1, Issue 1
Abstract
In the past decade, five oral nucleos(t)ide analogs and two formulations of pegylated interferon alpha have been approved for the treatment of chronic hepatitis B (CHB). Due to low personal income and inadequate health care system, low-to-moderate genetic barrier antiviral drugs are still widely used in China, which brings increased suboptimal response, viral relapse and resistance in real-life clinical practice. Combination therapy is a relative good approach to deal with these dilemma in Chinese CHB patients, and the strategies include de novo combination, rescue combination therapy, and optimized combination therapy. At present, combination therapy could be sonsidered for those who have suboptimal response to antiviral drugs, at high risk of complications in the event of virological breakthrough/rebound, or already with drug-resistant hepatitis B virus infection.
Authors and Affiliations
Chen En-Qiang
Keywords
Related Articles
- EP ID EP558564
- DOI 10.17352/ahr.000001
- Views 49
- Downloads 0
Active Navigation in a Hepatitis B Program: Screening, Vaccination and Patient Assistance for Asian Americans in Michigan
Background: Hepatitis B (HBV) is one of the greatest health disparities among Asian Americans. A team of volunteers in Southeast Michigan has studied HBV among Asian Americans in Michigan for 10 years. The study looked a...
Hepatitis E: Diagnostic and Therapeutic Challenges
HEV infection may be symptomatic or asymptomatic that has affected about one-third of world population with a case fatality rate of 1-2%, including 20-30% of infected pregnant women [3-5]. Though inherently hepatotropic...
The correlation between serum cytokine levels and liver cirrhosis in chronic hepatitis B patients: A meta-analysis
Background: The harm of liver cirrhosis (LC) is serious, and the development of LC is primarily resulted from chronic hepatitis B virus (HBV) in high-risk such as China and Africa and chronic hepatitis C virus (HCV) in d...
Management of Hepatitis C Infection with Direct Action Antiviral Drugs (DAA)**
Several new direct action antiviral drugs (DAA) against the HCV virus (HCV) are approved and marketed. The combination of DAA with pegylated interferon and ribavirin (PR) is only recommended to patients with tolerance to...
Constipation during Entecavir treatment in Chronic Hepatitis B patients: Two Cases Reports
Entecavir (ETV) is an oral nucleoside analog inhibitor of hepatitis B virus (HBV) DNA polymerase, which is widely used in patients with chronic hepatitis B (CHB). Despite the excellent safety data of this agent, the adve...